Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients
- PMID: 37224415
- DOI: 10.1111/jgs.18414
Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients
Abstract
Background: Medication-related osteonecrosis of the jaw (MRONJ) is clinically defined as a non-healing jawbone ulcerative-necrotic lesion appearing after dental therapy or minor trauma in patients treated previously with anti-resorptive, anti-angiogenic or immunomodulators. Older patients with osteoporosis and cancer receive these pharmacological agents regularly. As these patients are long-term survivors, efficient treatment is of paramount importance for their quality of life.
Methods: Literature searches via PubMed were conducted to identify relevant MRONJ studies. Basic information on MRONJ classification, clinical features, and pathosphysiology is presented herein as well as various clinical studies dealing with MRONJ in patients with osteoporosis and cancer. Lastly, we discuss current managment of patients and new trends in treatment of MRONJ.
Results: Although close follow-up and local hygiene have been advocated by some authors, severe forms of MRONJ are not responsive to conservative therapy. At present, there is no "gold standard" therapy for this condition. However, as the physiopathological basis of MRONJ is represented by the anti-angiogenic action of various pharmacological agents, new methods to increase and promote local angiogenesis and vascularization have recently been successfully tested in vitro, limited preclinical studies, and in a pilot clinical study.
Conclusions: It appears that the best method implies application on the lesion of endothelial progenitor cells as well as pro-angiogenic factors such as Vascular Endothelial Growth Factor (VEGF) and other related molecules. More recently, scaffolds in which these factors have been incorporated have shown positive results in limited trials. However, these studies must be replicated to include a large number of cases before any official therapeutic protocol is adopted.
Keywords: MRONJ; bisphosphonates; bone resorption; denosumab; osteoporosis.
© 2023 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.
References
REFERENCES
-
- Wat WZM. Current controversies on the pathogenesis of medication-related osteonecrosis of the jaw. Dent J (Basel). 2016;4(4):38. doi:10.3390/dj4040038
-
- Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update [published correction appears in J Oral Maxillofac Surg. 2015 Jul;73(7):1440] [published correction appears in J Oral Maxillofac Surg. 2015 Sep;73(9):1879]. J Oral Maxillofac Surg. 2014;72(10):1938-1956. doi:10.1016/j.joms.2014.04.031
-
- Migliorati CA. Oral complications in cancer patients-medication-related osteonecrosis of the jaw (MRONJ). Front Oral Health. 2022;3:866871. doi:10.3389/froh.2022.866871
-
- Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142(11):1243-1251. doi:10.14219/jada.archive.2011.0108
-
- Mark AM. What is MRONJ? J Am Dent Assoc. 2021;152(8):710. doi:10.1016/j.adaj.2021.05.016
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
